|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
DE69233013T2
(de)
|
1991-08-20 |
2004-03-04 |
The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer |
Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
|
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
|
EP1024198A3
(en)
|
1992-12-03 |
2002-05-29 |
Genzyme Corporation |
Pseudo-adenoviral vectors for the gene therapy of haemophiliae
|
|
EP0705344B8
(en)
|
1993-06-24 |
2006-05-10 |
Advec Inc. |
Adenovirus vectors for gene therapy
|
|
AU687117B2
(en)
|
1993-10-25 |
1998-02-19 |
Canji, Inc. |
Recombinant adenoviral vector and methods of use
|
|
US7078387B1
(en)
|
1998-12-28 |
2006-07-18 |
Arch Development Corp. |
Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
|
|
US6287860B1
(en)
|
2000-01-20 |
2001-09-11 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of MEKK2 expression
|
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
AU2007223855B2
(en)
|
2006-03-06 |
2013-05-16 |
Amunix Operating Inc. |
Unstructured recombinant polymers and uses thereof
|
|
JP2010536341A
(ja)
|
2007-08-15 |
2010-12-02 |
アムニクス， インコーポレイテッド |
生物学的に活性なポリペプチドの特性を改変するための組成物および方法
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
ES2610356T3
(es)
|
2009-02-03 |
2017-04-27 |
Amunix Operating Inc. |
Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
|
|
PL2504364T3
(pl)
|
2009-11-24 |
2017-12-29 |
Medimmune Limited |
Ukierunkowane środki wiążące przeciwko B7-H1
|
|
US9205144B2
(en)
|
2011-06-03 |
2015-12-08 |
Dana-Farber Cancer Institute, Inc. |
Identification of conserved peptide blocks in homologous polypeptides
|
|
RS61173B1
(sr)
*
|
2013-01-15 |
2021-01-29 |
Memorial Sloan Kettering Cancer Center |
Imunogeni wt-1 peptidi i postupci za njihovu upotrebu
|
|
WO2015195531A2
(en)
|
2014-06-18 |
2015-12-23 |
Albert Einstein College Of Medicine, Inc. |
Syntac polypeptides and uses thereof
|
|
DK3186283T3
(da)
|
2014-08-29 |
2020-03-02 |
Hoffmann La Roche |
Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1
|
|
EP4406604A3
(en)
|
2015-03-05 |
2024-10-23 |
Fred Hutchinson Cancer Center |
Immunomodulatory fusion proteins and uses thereof
|
|
MX383464B
(es)
|
2015-07-13 |
2025-03-14 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
|
|
SMT202200370T1
(it)
*
|
2015-11-20 |
2022-11-18 |
Memorial Sloan Kettering Cancer Center |
Composizione per il trattamento del cancro
|
|
WO2017201210A1
(en)
*
|
2016-05-18 |
2017-11-23 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
ES2973548T3
(es)
*
|
2016-12-22 |
2024-06-20 |
Cue Biopharma Inc |
Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
|
|
US20200010528A1
(en)
*
|
2017-03-15 |
2020-01-09 |
Cue Biopharma, Inc. |
Methods for modulating an immune response
|
|
CN119409836A
(zh)
*
|
2017-03-17 |
2025-02-11 |
弗雷德哈钦森癌症中心 |
免疫调节融合蛋白及其用途
|
|
EP3678691A4
(en)
*
|
2017-09-07 |
2021-06-09 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
JP2020534352A
(ja)
*
|
2017-09-07 |
2020-11-26 |
キュー バイオファーマ，インコーポレーテッド |
コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法
|
|
WO2020132366A2
(en)
*
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
|
|
WO2020132365A2
(en)
*
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
|
|
EP3897690A4
(en)
*
|
2018-12-19 |
2022-09-28 |
Cue Biopharma, Inc. |
T LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
|
|
CA3146591A1
(en)
*
|
2019-09-20 |
2021-03-25 |
Ronald D. Seidel Iii |
T-cell modulatory polypeptides and methods of use thereof
|
|
US20230117521A1
(en)
*
|
2020-03-25 |
2023-04-20 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
|
|
WO2021231376A2
(en)
*
|
2020-05-12 |
2021-11-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
AU2022238389A1
(en)
*
|
2021-03-19 |
2023-10-05 |
Cue Biopharma, Inc. |
T-cell modulatory polypeptides and methods of use thereof
|